Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Liabilities: 2019-2024

Historic Total Liabilities for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $44.3 million.

  • Keros Therapeutics' Total Liabilities fell 15.58% to $39.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.2 million, marking a year-over-year decrease of 15.58%. This contributed to the annual value of $44.3 million for FY2024, which is 17.25% up from last year.
  • Per Keros Therapeutics' latest filing, its Total Liabilities stood at $44.3 million for FY2024, which was up 17.25% from $37.8 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Total Liabilities ranged from a high of $44.3 million in FY2024 and a low of $7.7 million during FY2020.
  • Over the past 3 years, Keros Therapeutics' median Total Liabilities value was $37.8 million (recorded in 2023), while the average stood at $37.2 million.
  • In the last 5 years, Keros Therapeutics' Total Liabilities fell by 26.18% in 2020 and then spiked by 143.09% in 2022.
  • Yearly analysis of 5 years shows Keros Therapeutics' Total Liabilities stood at $7.7 million in 2020, then surged by 56.40% to $12.1 million in 2021, then skyrocketed by 143.09% to $29.4 million in 2022, then grew by 28.80% to $37.8 million in 2023, then increased by 17.25% to $44.3 million in 2024.